Erica Andersen‐Nissen
A5070983913- HIV Research and Treatment
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- vaccines and immunoinformatics approaches
- Immunotherapy and Immune Responses
- Vaccine Coverage and Hesitancy
- Single-cell and spatial transcriptomics
- Tuberculosis Research and Epidemiology
- Immune Response and Inflammation
- Herpesvirus Infections and Treatments
- Immune responses and vaccinations
- Pneumocystis jirovecii pneumonia detection and treatment
- Virology and Viral Diseases
- HIV/AIDS Research and Interventions
- Immune cells in cancer
- SARS-CoV-2 and COVID-19 Research
- Systemic Lupus Erythematosus Research
- Hepatitis C virus research
- Immunodeficiency and Autoimmune Disorders
- Hepatitis B Virus Studies
- HIV/AIDS drug development and treatment
- Antimicrobial Peptides and Activities
- Amoebic Infections and Treatments
- Vibrio bacteria research studies
- Escherichia coli research studies
Fred Hutch Cancer Center
2013-2025
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2012-2025
South African Tuberculosis Vaccine Initiative
2023
Cancer Research Center
2012-2016
University of Washington
2003-2016
Hutchinson (United Kingdom)
2015
Cape Town Science Centre
2014
Institute for Systems Biology
2003-2007
InSysBio (Russia)
2007
Institute for Biological Sciences
2005
The simultaneous measurement of multiple modalities represents an exciting frontier for single-cell genomics and necessitates computational methods that can define cellular states based on multimodal data. Here, we introduce "weighted-nearest neighbor" analysis, unsupervised framework to learn the relative utility each data type in cell, enabling integrative analysis modalities. We apply our procedure a CITE-seq dataset 211,000 human peripheral blood mononuclear cells (PBMCs) with panels...
Toll-like receptor 5 (TLR5) recognizes an evolutionarily conserved site on bacterial flagellin that is required for flagellar filament assembly and motility. The α ε Proteobacteria , including the important human pathogens Campylobacter jejuni Helicobacter pylori Bartonella bacilliformis require motility to efficiently infect mammalian hosts. In this study, we demonstrate these bacteria make molecules are not recognized by TLR5. We map responsible TLR5 evasion amino acids 89-96 of N-terminal...
Abstract The simultaneous measurement of multiple modalities, known as multimodal analysis, represents an exciting frontier for single-cell genomics and necessitates new computational methods that can define cellular states based on data types. Here, we introduce ‘weighted-nearest neighbor’ unsupervised framework to learn the relative utility each type in cell, enabling integrative analysis modalities. We apply our procedure a CITE-seq dataset hundreds thousands human white blood cells...
Abstract Although TLR5 regulates the innate immune response to bacterial flagellin, it is unclear whether its function essential during in vivo murine infections. To examine this question, we challenged Tlr5−/− mice transurethrally with Escherichia coli. At 2 days postinfection, wild-type exhibited increased inflammation of bladder comparison mice. By day 5 had significantly more bacteria bladders and kidneys showed both organs. In addition, flagellin induced high levels cytokine chemokine...
The molecular basis for Toll-like receptor (TLR) recognition of microbial ligands is unknown. We demonstrate that mouse and human TLR5 discriminate between different flagellins, we use this difference to map the flagellin site on 228 amino acids extracellular domain. Through modeling ectodomain, identify two conserved surface-exposed regions. Mutagenesis studies naturally occurring acid variation in residue 268 responsible discrimination molecules. Mutations within one surface residues D295...
To better understand how innate immune responses to vaccination can lead lasting protective immunity, we used a systems approach define signatures in humans over 1 wk following MRKAd5/HIV that predicted subsequent HIV-specific T-cell responses. Within 24 h, striking increases peripheral blood mononuclear cell gene expression associated with inflammation, IFN response, and myeloid trafficking occurred, lymphocyte-specific transcripts decreased. These alterations were corroborated by marked...
Abstract Bystander activation of memory T cells occurs in the absence cognate antigen during infections that elicit strong systemic inflammatory responses, which subsequently affect host immune responses. Here we report cell bystander is not limited to induction by inflammation. We initially observe potential a cohort human vaccine recipients. Using mouse model system, then find CD8 + are specifically recruited sites with activated antigen-presenting (APCs) CXCR3-dependent manner. In...
We report a 23% asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) Omicron carriage rate in participants being enrolled into clinical trial South Africa, 15-fold higher than trials before Omicron. also found lower CD4 + T-cell counts persons with human immunodeficiency virus (HIV) strongly correlated increased odds of SARS-CoV-2 polymerase chain reaction (PCR) positive.
In South Africans, the RV144 HIV vaccine regimen elicited robust immune responses that have been associated with efficacy.
BackgroundTuberculosis (TB) remains the leading cause of infectious disease-related death. Recently, a trial BCG revaccination and vaccination with H4:IC31, recombinant protein vaccine, in South African adolescents (Aeras C-040-404) showed efficacy preventing sustained QuantiFERON (QFT) conversion, proxy for Mycobacterium tuberculosis (M.tb) infection. A phase 1b 84 was conducted, concurrent Aeras C-040-404, to assess safety immunogenicity H56:IC31 revaccination, identify optimize immune...
Abstract Background The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates of HIV-1 acquisition risk RV144 measured HVTN and evaluated as Methods Among 1893 female vaccinees, 60 HIV-1–seropositive cases matched seronegative noncases sampled. HIV-specific CD4+ T-cell binding antibody responses 2 weeks after fourth fifth...
CD1 proteins evolved to present diverse lipid Ags T cells. In comparison with MHC proteins, exhibit minimal allelic diversity as a result of nonsynonymous single nucleotide polymorphisms (SNPs). However, it is unknown if common SNPs in gene regulatory regions affect expression and function. We report surprising patterns inducible CD1a on human dendritic cells (DCs), spanning the full range from undetectable high density, finding not seen other isoforms. CD1a-deficient DCs failed...
Abstract Background The Pox-Protein Public-Private Partnership is performing a suite of trials to evaluate the bivalent subtype C envelope protein (TV1.C and 1086.C glycoprotein 120) vaccine in context different adjuvants priming agents for human immunodeficiency virus (HIV) type 1 (HIV-1) prevention. Methods In HIV Vaccine Trials Network 111 trial, we compared safety immunogenicity DNA prime followed by DNA/protein boost with coadministration injected intramuscularly via either...
The pox-protein regimen tested in the RV144 trial is only vaccine strategy demonstrated to prevent HIV-1 infection. Subsequent analyses identified antibody and cellular immune responses as correlates of risk (CoRs) for HIV Early predictors these CoRs could provide insight into vaccine-induced protection guide efforts enhance efficacy. Using specimens from a phase 1b HIV-1-uninfected South Africans (HVTN 097), we profiled innate first ALVAC-HIV immunization. PBMC transcriptional peaked 1 day...
Background Adjuvants are widely used to enhance and/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared elicited by MF59 versus alum adjuvants in the RV144-like HIV vaccine regimen modified for Southern African region. The RV144 of a recombinant canarypox vector expressing env subtype B (ALVAC-HIV) prime followed ALVAC-HIV plus bivalent gp120 protein boost adjuvanted with is only have shown modest efficacy. Data generated after suggested...
Developing an effective HIV vaccine is a momentous challenge. An exceptionally wide range of candidate vaccines have been tested, yet many were poorly immunogenic, and the select few that advanced into efficacy trials, only one demonstrated any efficacy. Here we report results largest-scale cross-protocol immunogenicity comparison to date: 13 trials (including 36 regimens) conducted across nine countries worldwide, strengthened by standardized trial designs, validated assays in centralized...
An effective vaccine is required to end the HIV pandemic. We evaluated safety and immunogenicity of a DNA (DNA-HIV-PT123) with low- or high-dose bivalent (TV1.C 1086.C glycoprotein 120) subtype C envelope protein combinations, adjuvanted MF59 AS01B.
Abstract A 26‐color staining panel was developed to profile human antigen‐specific T cells in an intracellular cytokine (ICS) assay using peptide pools various antigens of interest. In addition multiple functional markers, the includes differentiation/activation markers and assess γδ, mucosal‐associated invariant T, NK as well conventional cells. Panel optimization performed previously cryopreserved PBMC from healthy adults, then, expression key cross‐validated against a validated ICS used...